Marshall Wace, LLP Hutchmed (China) LTD Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$16.25 - $20.23 $24,375 - $30,345	1,500 Added 9.74%	16,900 $306,000
Q3 2023 Nov 14, 2023	SELL	$11.85 - $16.95 $303,004 - $433,411	-25,570 Reduced 62.41%	15,400 $260,000
Q2 2023 Aug 14, 2023	BUY	$10.78 - $17.73 $182,257 - $299,761	16,907 Added 70.26%	40,970 $491,000
Q1 2023 May 15, 2023	BUY	$13.02 - $19.87 $313,300 - $478,131	24,063 New	24,063 $313,000
Q2 2021 Aug 13, 2021	SELL	$23.7 - $39.27 $912,639 - $1.51 Million	-38,508 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$27.01 - $36.8 $1.04 Million - $1.42 Million	38,508 New	38,508 $1.09 Million
Q4 2019 Feb 14, 2020	SELL	$17.17 - $25.95 $176,181 - $266,272	-10,261 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$17.84 - $22.69 $183,056 - $232,822	10,261 New	10,261 $183,000

8.25M

3.8K

2.4K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.